The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
November 23rd 2024
With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.
November 18th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Study Underlines Importance of COVID Vaccine Booster Doses in Transplant Recipients
August 16th 2023A study led by Massachusetts General Hospital is offering insight into the antibody response achieved with each dose of mRNA vaccines among heart and lung transplant recipients relative to their healthy counterparts.
Diabetes Dialogue: Implications of SELECT Trial and Brenzavvy on Cost Plus Drugs
August 15th 2023In this episode, hosts take time to break down the implications of two, potentially paradigm-shifting news in the announcement of the addition of bexagliflozin to the Cost Plus Drugs platform and topline data from the landmark SELECT trial.
Addressing Inflammation and Role of Colchicine in ASCVD, with Michael J. Blaha, MD, MPH
August 10th 2023Michael J. Blaha, MD, MPH, discusses his interpretation of the growing data detailing the role of inflammation as a driver of cardiovascular risk and how clinicians can identify patients who stand to benefit most from colchicine 0.5 mg tablets.
GLP-1 RAs and the Evolving Role of Cardiologists in Obesity Management, with Michael Blaha, MD
August 8th 2023In a recent Q&A, Michael Blaha, MD, discusses how he views the ideal role of cardiologists in the management of obesity and how this role could change based on the results of the SELECT trial.
SELECT Trial Shows Semaglutide 2.4 mg Could Reduce Cardiovascular Risk
August 8th 2023Novo Nordisk has announced topline data from the SELECT trial, which suggest use of once-weekly semaglutide 2.4 mg was associated with a statistically significant 20% reduction in 3-point MACE among a cohort with overweight or obesity and established cardiovascular disease.
Daily Soft Drink Consumption Increases Obesity, Overweight Rates in Adolescents
July 27th 2023A cross-sectional analysis of more than 100 countries and regions revealed a statistically significant association between the prevalence of daily soft drink consumption and the prevalence of overweight and obesity.
Risk of Brain Bleeds with Aspirin May Outweigh Stroke Reduction Benefit for Older Adults
July 26th 2023A secondary analysis of ASPREE is bringing the role of aspirin in primary prevention settings further into question, suggesting daily use of low-dose aspirin was associated with a 38% increase in intracranial bleeding in older adults.
Pregnancy Loss Linked to Increased Risk of Heart Attack in Women, But Not Male Partners
July 26th 2023A study from Denmark leveraging more than 40 million years of follow-up data from patients dating back to the 1950s offers insight into the apparent increase in the risk of myocardial infarction associated with pregnancy loss in women and whether this same effect is observed in male partners.
Disparities in Statin Use for ASCVD Unexplained by Disease Severity, Structural Factors
July 24th 2023A cross-sectional analysis suggests disparities in statin use for several race–ethnicity–gender groups were not explained by ASCVD severity or structural factors, including socioeconomic status and health insurance.
Zilebesiran, an RNA Interference Agent, Shows Promise for Hypertension in Phase 1 Trial
July 24th 2023A multipart, phase 1 trial provides evidence demonstrating the safety of zilebesiran, an RNA interference agent, which appeared to have a favorable safety profile among adult patients with hypertension.
Statin Therapy Could Reduce Cardiovascular Events in People with HIV
July 24th 2023New data presented at the 12th International AIDS Society Conference on HIV Science suggests use of statin therapy in a primary prevention cohort of patients with HIV on antiretroviral therapy was associated with a 35% reduction in risk of cardiovascular events.